GeneDx Holdings Corp. (WGS) stock
WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3049% above fair value
$47.29−3.73 (-7.31%)
Close on Nov 17, 2026Market cap $1.41BP/E –Yield –
GeneDx revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
GeneDx's revenue for the twelve months ending Jun 30, 2026 was $454.43M, up 25.4% year over year. For fiscal 2025 it was $427.54M, up 40.0% from the year before. The highest annual figure on record is $427.54M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $427.54M | +40.0% |
| FY2024 | Dec 31, 2024 | $305.45M | +50.8% |
| FY2023 | Dec 31, 2023 | $202.57M | -13.7% |
| FY2022 | Dec 31, 2022 | $234.69M | +10.6% |
| FY2021 | Dec 31, 2021 | $212.20M | +18.3% |
| FY2020 | Dec 31, 2020 | $179.32M | -8.6% |
| FY2019 | Dec 31, 2019 | $196.17M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $114.44M | +11.4% |
| Q1 FY2026 | Mar 31, 2026 | $102.25M | +17.4% |
| Q4 FY2025 | Dec 31, 2025 | $120.99M | +26.5% |
| Q3 FY2025 | Sep 30, 2025 | $116.74M | +51.9% |
| Q2 FY2025 | Jun 30, 2025 | $102.69M | +45.6% |
| Q1 FY2025 | Mar 31, 2025 | $87.12M | +39.6% |
| Q4 FY2024 | Dec 31, 2024 | $95.64M | +66.6% |
| Q3 FY2024 | Sep 30, 2024 | $76.87M | +44.2% |
| Q2 FY2024 | Jun 30, 2024 | $70.51M | +44.8% |
| Q1 FY2024 | Mar 31, 2024 | $62.42M | +44.7% |
| Q4 FY2023 | Dec 31, 2023 | $57.42M | -6.4% |
| Q3 FY2023 | Sep 30, 2023 | $53.30M | -36.0% |
| Q2 FY2023 | Jun 30, 2023 | $48.71M | +34.7% |
| Q1 FY2023 | Mar 31, 2023 | $43.14M | -20.0% |
| Q4 FY2022 | Dec 31, 2022 | $61.35M | +6.1% |
| Q3 FY2022 | Sep 30, 2022 | $83.23M | +92.8% |
| Q2 FY2022 | Jun 30, 2022 | $36.17M | -23.1% |
| Q1 FY2022 | Mar 31, 2022 | $53.94M | -16.0% |
| Q4 FY2021 | Dec 31, 2021 | $57.80M | -9.6% |
| Q3 FY2021 | Sep 30, 2021 | $43.18M | +11.8% |
| Q2 FY2021 | Jun 30, 2021 | $47.02M | +56.2% |
| Q1 FY2021 | Mar 31, 2021 | $64.20M | +37.6% |
| Q4 FY2020 | Dec 31, 2020 | $63.96M | – |
| Q3 FY2020 | Sep 30, 2020 | $38.61M | – |
| Q2 FY2020 | Jun 30, 2020 | $30.10M | – |
| Q1 FY2020 | Mar 31, 2020 | $46.66M | – |
See a number that looks wrong?